UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

Stroke (1970), 2012-06, Vol.43 (6), p.1711-1737

2012

Volltextzugriff (PDF)

Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry

Circulation (New York, N.Y.), 2014-04, Vol.129 (15), p.1568-1576

2014

Volltextzugriff (PDF)

Risk Factors for Infections Involving Cardiac Implanted Electronic Devices

Journal of the American College of Cardiology, 2019-12, Vol.74 (23), p.2845-2854

2019

Volltextzugriff (PDF)

Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation

Heart rhythm, 2017-06, Vol.14 (6), p.801-807

2017

Volltextzugriff (PDF)

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

The Lancet (British edition), 2020-11, Vol.396 (10264), p.1745-1757

2020

Volltextzugriff (PDF)

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial

Thrombosis and haemostasis, 2015-03, Vol.113 (3), p.625-632

2015

Volltextzugriff (PDF)

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

Circulation (New York, N.Y.), 2013-02, Vol.127 (5), p.634-640

2013

Volltextzugriff (PDF)

Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction

The New England journal of medicine, 2004-12, Vol.351 (24), p.2481-2488

2004

Volltextzugriff (PDF)

Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial

Stroke (1970), 2012-06, Vol.43 (6), p.1511-1517

2012

Volltextzugriff (PDF)

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Circulation (New York, N.Y.), 2012-02, Vol.125 (5), p.669-676

2012

Volltextzugriff (PDF)

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Circulation (New York, N.Y.), 2012-04, Vol.125 (13), p.1605-1616

2012

Volltextzugriff (PDF)

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Circulation (New York, N.Y.), 2014-03, Vol.129 (9), p.961-970

2014

Volltextzugriff (PDF)

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Circulation (New York, N.Y.), 2012-07, Vol.126 (3), p.343-348

2012

Volltextzugriff (PDF)

Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial

Journal of the American College of Cardiology, 2015-06, Vol.65 (23), p.2481-2493

2015

Volltextzugriff (PDF)

Canadian implantable defibrillator study (CIDS) : A randomized trial of the implantable cardioverter defibrillator against amiodarone

Circulation (New York, N.Y.), 2000-03, Vol.101 (11), p.1297-1302

2000

Volltextzugriff (PDF)

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Circulation (New York, N.Y.), 2011-05, Vol.123 (21), p.2363-2372

2011

Volltextzugriff (PDF)

Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

Circulation (New York, N.Y.), 2012-11, Vol.126 (19), p.2309-2316

2012

Volltextzugriff (PDF)

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial

Annals of internal medicine, 2011-11, Vol.155 (10), p.660

2011

Volltextzugriff (PDF)

Genetic variation in the human leukocyte antigen region confers susceptibility to Clostridioides difficile infection

Scientific reports, 2023-10, Vol.13 (1), p.18532-18532, Article 18532

2023

Volltextzugriff (PDF)

Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)

The American journal of cardiology, 2015-10, Vol.116 (8), p.1204-1209

2015

Volltextzugriff (PDF)

Neurocognitive Performance in Hypertensive Patients after Spine Surgery

Anesthesiology (Philadelphia), 2009-02, Vol.110 (2), p.254-261

2009

Volltextzugriff (PDF)

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

The American heart journal, 2017-08, Vol.190, p.94-103

2017

Volltextzugriff (PDF)

Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial

European journal of heart failure, 2013-09, Vol.15 (9), p.1053-1061

2013

Volltextzugriff (PDF)

Communicable diseases in complex emergencies: impact and challenges

The Lancet (British edition), 2004-11, Vol.364 (9449), p.1974-1983

2004

Volltextzugriff (PDF)

Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation

The American heart journal, 2005-03, Vol.149 (3), p.489-496

2005

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Aktive Filter

ThemaRisk Factors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(63)

Sprache

Englisch
(63)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry

Risk Factors for Infections Involving Cardiac Implanted Electronic Devices

Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction

Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial

Canadian implantable defibrillator study (CIDS) : A randomized trial of the implantable cardioverter defibrillator against amiodarone

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial

Genetic variation in the human leukocyte antigen region confers susceptibility to Clostridioides difficile infection

Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)

Neurocognitive Performance in Hypertensive Patients after Spine Surgery

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial

Communicable diseases in complex emergencies: impact and challenges

Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation

Aktive Filter

Suchergebnisse filtern